September Agenda

Improving Access to Mental Healthcare

Perhaps one of the greatest hindrances to positive outcomes for patients with psychiatric issues is difficulty in accessing and adhering to timely, appropriate, and ongoing mental health care. This half-day program will explore how long-acting injectable psychotropics and prescription digital therapeutics may improve access to care and outcomes for patients with psychiatric conditions, including those with serious mental illness.

All sessions will be held in Pacific Time (PT).

Saturday, September 28, 2024

7:00 am - 8:00 am

Not Just a Long Shot: Strategies to Ensure Continuity of Care for Patients with Serious Mental Illness

Jonathan M. Meyer, MD

In the absence of continuous treatment, many patients with serious mental illness (including the spectrums of schizophrenia and mood disorders) are at great risk for relapse, hospitalization, and incarceration. In this presentation, Dr. Jonathan Meyer will explore strategies, including use of long-acting injectable psychotropics, for improving continuity of care and outcomes (e.g., reduced criminalization) for patients suffering with serious mental illness.

8:00 am - 9:00 am

Industry Session^†: Rethinking Systems in Schizophrenia: Acetylcholine and Muscarinic Receptors

Rakesh Jain, MD, MPH

An exciting and interactive program discussing a new understanding of acetylcholine, muscarinic receptors, and schizophrenia.

Sponsored by Bristol Myers Squibb

9:00 am – 9:05 am

Break

9:05 am – 10:05 am

Mind Games: Connecting Patients to Mental Healthcare Using Digital Applications

William M. Sauvé, MD

Prescription digital therapeutics (PDTs) are quickly becoming a valuable addition to the treatment armamentarium for a wide variety of mental health conditions. Not only can PDTs complement existing pharmacological and non-pharmacological treatment strategies, but their digital nature also allows for widespread use among patient populations that may otherwise have challenges in accessing continuous care. Here, Dr. William Sauvé discusses the utility and practical application of FDA-approved and emerging digital therapeutics for the treatment of mental health concerns as well as providing valuable insight as to the neurobiological basis for the efficacy of PDTs in the treatment of psychiatric issues.

10:05 am – 10:30 am

Live Panel Q&A

Jonathan M. Meyer, MD and William M. Sauvé, MD

^†The content of all non-CME/CE events (Industry Sessions, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.

Program Faculty

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Dr. Jonathan Meyer is a Voluntary Clinical Professor of Psychiatry at University of California, San Diego, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Meyer is a graduate of Stanford University and Harvard Medical School, finished his adult psychiatry residency at LA County-USC Medical Center and completed fellowships there in Consultation/Liaison Psychiatry and Psychopharmacology Research. Dr. Meyer has teaching duties at UC San Diego and the Balboa Naval Medical Center in San Diego and is a consultant to the first episode psychosis program at Balboa NMC. 

Dr. Meyer has lectured and published extensively on psychopharmacology and is the sole author of the chapter on the Pharmacotherapy of Psychosis and Mania for the last 3 editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics. Along with Dr. Stephen Stahl he is co-author of The Clozapine Handbook published in 2019, The Clinical Use of Antipsychotic Plasma Levels published in 2021, and The Lithium Handbook published in 2023. 

William M. Sauvé, MD

Regional Medical Director—Virginia, Greenbrook TMS NeuroHealth Centers

Dr. William M. Sauvé is a Regional Medical Director for Greenbrook TMS NeuroHealth Centers, a dedicated center for the treatment of depression and OCD using Transcranial Magnetic Stimulation. 

After receiving his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, Dr. Sauvé completed his residency in adult psychiatry in the National Capital Consortium in Washington, DC, which includes the National Naval Medical Center in Bethesda, Walter Reed Army Medical Center in Washington, DC, and Malcolm Grow Medical Center at Andrews Air Force Base in Maryland. Shortly afterward, he was deployed to the Al Anbar Province, Iraq, as the regimental psychiatrist for the 7th Marine Regiment. After 11 years of active-duty service, he left the US Navy to become Military Clinical Director at Poplar Springs Hospital. After 3 years there, he left hospital work to dedicate his full time to Transcranial Magnetic Stimulation, a practice that has now grown to over 100 dedicated TMS centers around the country. Dr. Sauvé is certified by the American Board of Psychiatry and Neurology, Inc. 

Dr. Sauvé coauthored “The Science of Transcranial Magnetic Stimulation” with Laurence Crowther for the July issue of Psychiatric Annals. He is a member of the American Psychiatric Association and a Faculty Member at the Neuroscience Education Institute. 